MESO
Mesoblast Ltd
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Mesoblast Ltd
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Mesoblast has 5 disclosed suppliers and 6 disclosed customers in SEC filings.
Mesoblast Ltd
14.79
Expected move
No implied move.
News
Linked news
NewsSentenceIn April 2026, the Group engaged Doculogics, Inc. ("Doculogics") to provide electronic publishing services, including publishing software incorporating artificial intelligence capability, in support of the Group's Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for its chronic heart failure product.
MESO 20-Faccession 0001345099-26-000081
SentenceWe have a manufacturing service agreement with Lonza Bioscience Singapore Pte. Ltd. for the supply of commercial product of Ryoncil ® .
MESO 20-Faccession 0001345099-26-000081
SentenceUnder the MSA, we pay Lonza on a fee for service basis to provide us with manufacturing and supply capabilities for our MPC and MSP products, including records preparation, process validation, quality control, quality assurance, manufacturing and other related services.
MESO 20-Faccession 0001345099-26-000081
SentenceWe have manufactured clinical and commercial quantities of our mesenchymal lineage cell product candidates in manufacturing facilities owned by Lonza Walkersville, Inc. and Lonza Bioscience Singapore Pte. Ltd. (collectively referred to as "Lonza").
MESO 20-Faccession 0001345099-26-000081
SentenceIn April 2026, the Group acquired an exclusive worldwide license to a patented chimeric antigen receptor ("CAR") technology platform for precision-enhanced augmentation of therapeutic mesenchymal stromal cell ("MSC") products and related intellectual property developed from Mayo Clinic research.
MESO 20-Faccession 0001345099-26-000081
SentenceUnder the partnership, Grünenthal will have exclusive commercialization rights to MPC-06-ID for Europe and Latin America.
MESO 20-Faccession 0001345099-26-000081
SentenceWe have licensees, with rights to commercialize products based on our MSC technology, including JCR in Japan.
MESO 20-Faccession 0001345099-26-000081
SentenceUnder the JCR Agreement, JCR obtained rights in Japan to our MSCs, for the treatment of aGVHD.
MESO 20-Faccession 0001345099-26-000081
SentenceThe Development and Commercialization Agreement provides Tasly with exclusive rights to develop, manufacture and commercialize in China MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction.
MESO 20-Faccession 0001345099-26-000081
SentenceThe Development and Commercialization Agreement provides Tasly with exclusive rights to develop, manufacture and commercialize Revascor ® in China for the treatment or prevention of CHF and MPC-25-IC for the treatment or prevention of AMI. Tasly will fund all development, manufacturing and commercialization activities in China for Revascor ® and MPC-25-IC.
MESO 20-Faccession 0001345099-25-000067